Kimia Farma

What Kimia Farma does

PT Kimia Farma (Persero) Tbk is Indonesia's largest state-owned pharmaceutical company, with operations dating back to 1817 under Dutch colonial administration and a majority parent holding by PT Bio Farma (Persero) at 89.82%. The company operates an integrated pharmaceutical value chain spanning raw material manufacturing (KF Sungwun Pharmacopia, PT Sinkona Indonesia Lestari for quinine), finished-dose manufacturing of generic, ethical (prescription), OTC, herbal, and cosmetic products, and clinical/diagnostic services through PT Kimia Farma Diagnostika. Its go-to-market combines B2B distribution via 49 national distribution networks serving over 30,000 customer channels (hospitals, clinics, pharmacies, government programs) with B2C retail through more than 1,300 Kimia Farma Apotek outlets and more than 400 health, beauty, and home-care clinics, supported by a 24-hour pharmacist contact center (1500-255).

Revenue is generated across four streams: pharmaceutical manufacturing (product sales), pharmaceutical distribution (transaction-based margin on 30,000+ channels), pharmacy retail (recurring consumer purchases across 1,300+ outlets), and healthcare services (professional services including clinical labs, beauty clinics, and home healthcare). The company has begun expanding into advanced biotechnology through Stemxera stem cell therapy in partnership with RSCM and FKUI, and launched Fentakaf, a domestically manufactured painkiller injection, as an import-substitution play. A new "Healthy Ageing Ecosystem" targets a stated Rp 700 trillion addressable market.

Strategic positioning is anchored by state-owned enterprise (BUMN) status, which confers preferential access to government procurement and Indonesia's national health programs, partially offset by recent balance sheet stress: the EGMS of 3 November 2025 approved divestiture and write-off of 38 assets exceeding 50% of net assets (including Rp 347 billion Cikarang land sale to parent Bio Farma and 37 KPKNL-auctioned assets through 2029), alongside a series of mandatory convertible bond restructuring events through 2025–2026. The 2022 Rp 1.86 trillion strategic investment by China's Silk Road Fund and Indonesia Investment Authority into the Apotek subsidiary signals partial opening of the capital structure to foreign sovereign-linked capital while preserving BUMN control.

Name

Kimia Farma

Legal name

PT Kimia Farma (Persero) Tbk

Website

https://kimiafarma.co.id

Company type

Public

Founded year

1817

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Indonesia's largest state-owned pharmaceutical company (BUMN), operating an integrated value chain from raw materials through manufacturing, 49-distribution network, and 1,300+ retail pharmacies and 400+ clinics, serving consumers, hospitals, and government health programs across Indonesia.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (456110), Medicinal and Botanical Manufacturing (325411)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

akta.pro secondary industries

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)

Keywords

• Pharmaceutical manufacturing
• Pharmacy retail services
• Herbal medicine products
• Stem cell therapy
• Pharmaceutical distribution

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing: Manufacturing of ethical drugs, generic drugs, OTC medicines, herbal products, and cosmetics under Kimia Farma's own brand portfolio.
2. Pharmaceutical Distribution: Distribution of pharmaceutical products through 49 national distribution networks serving over 30,000 channels across Indonesia.
3. Pharmacy Retail: Operation of over 1,300 pharmacy retail outlets and 400+ health clinics providing healthcare services to end consumers.
4. Healthcare Services: Clinical laboratory services, health clinics, beauty clinics, and home healthcare services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Kimia Farma is Indonesia's largest state-owned pharmaceutical company that manufactures, distributes, and retails a comprehensive portfolio of pharmaceutical products including generic drugs, ethical (prescription) drugs, over-the-counter (OTC) medicines, herbal remedies, and cosmetics. The company also operates clinical laboratory services, health clinics, beauty clinics, home healthcare, and advanced biotechnology offerings including stem cell therapy (Stemxera). It runs an integrated value chain from raw material production through pharmaceutical manufacturing, a 49-network national distribution system, and over 1,300 pharmacy retail outlets across Indonesia.

Differentiator

Problem solved

Functional benefit

Brands

• Kimia Farma Apotek: Pharmacy retail chain operated by Kimia Farma Group
• Stemxera
• Kimia Farma Care
• KF Sungwun Pharmacopia
• Healthy Ageing Ecosystem

Products and services

• Generic Pharmaceuticals (Generik) Generic pharmaceutical products manufactured and sold under Kimia Farma's own brand, available through retail pharmacy outlets and institutional distribution channels for affordability-focused consumers and healthcare providers.
• Ethical (Prescription) Pharmaceuticals (Etikal) Prescription (ethical) pharmaceutical products distributed to healthcare providers, hospitals, and pharmacies across Indonesia through Kimia Farma's distribution network.
• OTC and Herbal Products Over-the-counter (OTC) medicines and herbal health products sold through Kimia Farma's retail pharmacy outlets and distribution channels to Indonesian consumers.
• Cosmetics Cosmetics products manufactured and distributed by Kimia Farma as part of its consumer health and personal care portfolio.
• Stemxera Stem Cell Therapy Stem cell therapy product and service offering under the Stemxera brand, expanding Kimia Farma's portfolio in advanced biotechnology treatments in collaboration with referral hospitals.
• Fentakaf Painkiller Injection Domestically manufactured pain-relief injection product launched by Kimia Farma for the Indonesian healthcare market.
• Kimia Farma Apotek Retail Pharmacy Services Retail pharmacy services operated through the Kimia Farma Apotek chain of over 1,300 outlets across Indonesia, providing consumer access to generic, ethical, OTC, and herbal pharmaceutical products.
• Health Clinic Services Integrated health clinic services provided through over 400 Kimia Farma clinics, including general clinical services and home healthcare for Indonesian consumers.
• Clinical Laboratory Diagnostic Services (Kimia Farma Diagnostika) Clinical laboratory and diagnostic services offered through PT Kimia Farma Diagnostika, supporting medical testing for consumers and partner healthcare institutions.
• Beauty Clinic Services Beauty clinic services provided through Kimia Farma's clinic network, offering aesthetic and cosmetic treatments to consumers.
• Pharmaceutical Distribution Services (Kimia Farma Trading & Distribution) National pharmaceutical distribution services operated through 49 distribution networks and over 30,000 customer channels, supplying hospitals, clinics, pharmacies, and other institutions with pharmaceutical products.
• Healthy Ageing Ecosystem Integrated ecosystem of healthcare products and services targeting Indonesia's healthy ageing market, combining pharmaceutical, clinic, laboratory, and biotechnology offerings under Kimia Farma's brand.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Fakultas Kedokteran Universitas Indonesia (FKUI)coreStrategic or Co-development PartnerStrategic collaboration with FKUI to strengthen commitment to national health programs through medical education and research partnerships.
• RSCM (Rumah Sakit Cipto Mangunkusumo)coreStrategic or Co-development PartnerPartnership to expand stem cell therapy services, bringing advanced biotechnology treatments to more patients in Indonesia through collaboration with the national referral hospital.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Dexa Medica: Major Indonesian pharmaceutical manufacturer (private, group includes Dexa Laboratories of Biomolecular Sciences and OTC consumer health brands). Directly comparable on Indonesian pharma manufacturing and branded generic competition.
• Combiphar: Indonesian pharmaceutical and consumer healthcare company operating in branded generics, OTC, and consumer wellness. Comparable on Indonesian market presence and consumer pharma portfolio overlap with Kimia Farma.
• Soho Global Health (PT Soho Industri Pharmasi): Indonesian pharmaceutical and consumer healthcare manufacturer producing branded generics, OTC, and herbal supplements. Comparable on Indonesian pharma manufacturing scale and traditional medicine overlap.
• Tempo Scan Pacific (PT Tempo Scan Pacific Tbk): Indonesian publicly-traded pharma and consumer healthcare company (IDX: TSPC) producing ethical, OTC, and consumer health products. Comparable on Indonesian pharma manufacturing, OTC product portfolio, and distribution scale.
• Kalbe Farma (PT Kalbe Farma Tbk): Indonesia's largest listed pharmaceutical company (IDX: KLBF), operating across prescription drugs, consumer health, distribution, and clinical labs. Most directly comparable to Kimia Farma on geographic market, business mix, and channel scale.
• Bio Farma (PT Bio Farma (Persero)): Indonesian state-owned vaccine and biopharmaceutical manufacturer that is Kimia Farma's 89.82% parent company. Highly comparable as the same state-owned pharma holding group; consolidates Kimia Farma financials.
• Indofarma (PT Indofarma Global Medika Tbk): Another Indonesian state-owned pharmaceutical company (BUMN) listed on IDX (ticker INAF), manufacturing and distributing generic and ethical drugs and operating pharmacies. Closely comparable on state-ownership, product mix, and tender-driven distribution model.
• Pyridam Farma (PT Pyridam Farma Tbk): Indonesian pharma manufacturer (IDX: PYFA) producing generics, OTC, and herbal medicines. Comparable on Indonesian pharmaceutical manufacturing scale and traditional medicine (herbal) segment.
• Phapros (PT Phapros Tbk): Indonesian listed pharmaceutical manufacturer (IDX: PEHA) focused on generic and ethical drugs, currently a subsidiary of Kimia Farma Group. Comparable on Indonesian pharma manufacturing, generics product line, and ownership by Bio Farma Group.

Broad incumbents

• PT Merck Tbk (Merck Indonesia): Listed Indonesian subsidiary of Germany's Merck KGaA (IDX: MERK), operating in pharmaceuticals, life sciences, and performance materials. Comparable as another listed Indonesian pharma manufacturer, though with multinational parent backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/kimiafarmaind
• Facebookfacebook.com/KimiaFarmaCare
• Instagraminstagram.com/kimiafarma.ind

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kimia Farma